A retrospective cohort analysis by Riley et al. [73] demonstrated that GLP-1 RA therapy significantly lowered the risk of major cardiovascular events, including acute MI and HF, in T2DM patients over five years compared with those receiving insulin alone. Here, GLP1R is linked to type 2 diabetes mellitus.